Hikma d.o.o.
<b>Xellia Pharmaceuticals</b> is a specialty pharmaceutical company developing, manufacturing and commercializing anti-infective treatments against serious and often life-threatening bacterial and fungal infections. Headquartered in Copenhagen, Denmark, Xellia has a global footprint with R&D, manufacturing and commercial operations across Europe, Asia, the Middle East and North America. Xellia is wholly owned by Novo Holdings A/S and employs a dedicated team of over 1,800 people.
With over 115 years of experience, Xellia is a world-leading trusted supplier of several important established anti-infective drugs, comprising active pharmaceutical ingredients as well as injectable products. Continuing the Company’s evolution, Xellia is generating an innovative pipeline of value-added anti-infective medicines intended to enhance patient care, providing convenience and ease of use for healthcare professionals.
Together you can help us lead the fight against infections.Plaće su porasle.
Pitanje je – gdje si ti u toj priči?
Odaberi najpoželjnijeg poslodavca i osvoji nagradu!
Osvoji iPhone 17, Poklon bon u vrijednosti 500€ ili Wellness vikend!
